The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed implementation of mirikizumab for treating Crohn’s Disease in line with NICE TA1080
Mirikizumab for this indication will be considered as RED on the Joint Formulary with treatment initiation and continued prescribing by specialists in gastroenterology.
Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD.
This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves mirikizumab as a treatment option in line with the recommendations made in NICE TA925, for treating moderately to severely active ulcerative colitis.
Mirikizumab for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.
